Agalsidase alfa and kidney dysfunction in Fabry disease

Area of Science:

• Biochemistry
• Genetics
• Nephrology

Background:

• Fabry disease is an X-linked disorder of glycosphingolipid metabolism.
• Deficient alpha-galactosidase A activity leads to progressive kidney dysfunction, often resulting in end-stage renal disease (ESRD) in males by the third decade.
• Enzyme replacement therapy (ERT) is a potential treatment strategy.

Purpose of the Study:

• To summarize the effects of agalsidase alfa on kidney function in adult male patients with Fabry disease.
• To evaluate the impact of agalsidase alfa on Glomerular Filtration Rate (GFR) and proteinuria.
• To identify predictors of GFR decline during ERT.

Main Methods:

• Analysis of data from three prospective, randomized, placebo-controlled trials and their open-label extensions.
• Inclusion of 108 adult male patients with Fabry disease.
• Measurement of GFR and proteinuria at baseline and during treatment.

Main Results:

• Agalsidase alfa treatment showed a slower annualized rate of GFR decline (-2.9 +/- 8.7 ml/min per 1.73 m(2)) compared to placebo (-7.0 +/- 32.9 ml/min per 1.73 m(2)) in nonhyperfiltrating patients.
• Agalsidase alfa did not significantly affect proteinuria levels.
• Baseline GFR and proteinuria category were significant predictors of GFR decline.

Conclusions:

• Agalsidase alfa may stabilize kidney function in male patients with Fabry disease.
• Early intervention and monitoring of GFR and proteinuria are crucial for managing Fabry nephropathy.
• This study represents the largest cohort evaluating ERT effects on kidney function in this population.